Abstract
• The inherent variability of admission and assessment of the PRAM adds noise to the data, which was taken into account in sample size KEYWORDS: asthma, corticosteroids, responsiveness, children, acute care, virus, cotinine, gene polymorphism, cohort 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1 Of all respiratory illnesses, asthma is one of the most frequent paediatric diagnoses requiring hospital admission. 1 The burden of illness is much higher in preschool-aged children, who account for over 50% of ED visits [1] [2] [3] [4] and who have three times the hospital admission rate of older children and adolescents. 5 The difficulty in measuring asthma severity in young children has resulted in a dearth of comparative therapeutic evidence between preschoolers and older children. [6] [7] [8] [9] Treatment of acute asthma National and international guidelines for the management of acute asthma recommend: (1) inhaled ß 2 -agonists for all patients, (2) systemic (usually oral) corticosteroids for those with moderate and severe asthma, and (3) repeated doses of inhaled β 2 -agonists and anticholinergics for severe cases. 6;7;9;10 The latter two recommendations independently reduce admission rates by 25% in studies of predominantly school-aged children. 11;12 Several features must be noted. First, recommendations are severity-specific; patients with mild asthma do not appear to benefit from oral corticosteroids. 11;13 Second, the concept of the "golden first hour of treatment" supports early and aggressive asthma management, as the risk of admission is only reduced when oral corticosteroids are administered 3 to 4 hours prior to the decision to admit. Third, of all treatments administered in the ED, oral corticosteroids are by far the most effective for preventing admission. 14 Fourth, there is no equally effective substitute for oral corticosteroids;
promising contenders such as high-dose inhaled steroids, 15 ;16 intravenous antileukotrienes, 17 or magnesium sulfate 18 have been shown to be inferior to oral corticosteroids and are used as add-on therapy. Fifth, systemic corticosteroids are inexpensive generic drugs. Short treatment with oral corticosteroids is generally devoid of significant side effects, 19 though rare cases of fatal or disseminated varicella have been reported. 20 Sixth, while recommendations are relatively similar in young children, older children, and adults, the evidence for the former is weaker due to the underrepresentation of preschool-aged children in relevant trials. 11;12 While oral corticosteroids are the cornerstone of management of acute, moderate or severe asthma, 6 several reports have recently shaken the belief that they are equally effective for all patients with asthma, showing that children with viral-induced wheezing 21 and smoking adults 22 are corticosteroid-resistant. Indeed, in a large placebo-controlled randomized controlled trial of 700 children aged 10-60 months with mild-to-moderate viral-induced wheezing, oral corticosteroid was not superior to placebo for reducing the length of stay in hospital or improving the PRAM clinical score, despite adequate study power. 21 Critics have suggested that: (1) in most children, the disease may not have been asthma (documented in only 16% of patients) but rather the North American definition of bronchiolitis; (2) some patients (with mild asthma) may not have needed corticosteroids; 23 (3) the prolonged stay in hospital did not seem supported by severity, 24 and (4) the dose of 1 (instead of 2) mg/kg may have been insufficient. Yet, this study elicited major discomfort regarding acute asthma management in young children. 24 In another, adequately powered, landmark trial, 2-week treatment with prednisone showed marked blunting of response in adult smokers, with an improvement in forced expiratory volume in 1 second of 237 mL (95% CI: 43, 431) in never-smokers compared to no change or 47 (-148, 243) mL in current smokers. 22 The question remains as to whether smoking adolescents and children with environmental tobacco smoke (ETS) respond as well as those not exposed.
None of these aforementioned findings have been replicated, thus prompting us to review the potential determinants of responsiveness.
Potential determinants of response
Disease diagnosis
Children with bronchiolitis do not respond to oral corticosteroids, although a recent trial has demonstrated a significant response only in association with nebulised epinephrine. [25] [26] [27] 
Upper respiratory tract infections (URTI)
URTIs, usually viral in origin, are the most frequent (60-80%) triggers of asthma exacerbation in children. [32] [33] [34] RSV, parainfluenza virus, and rhinovirus are frequently implicated in children under two years old, while picornavirus, coronavirus, and influenza are usually associated with asthma in older children. [35] [36] [37] [38] The incidence of viral-induced asthma peaks in September and continues throughout the fall and winter. 32 In adults with acute asthma, viral infection is associated with longer hospital admission 39 and increased sputum neutrophils, suggesting a predominantly neutrophilic airway inflammation. 39 In a study of children aged 3-36 months, those infected with rhinovirus showed fewer relapses when treated with oral prednisone compared to placebo, suggesting that rhinovirus did not impair responsiveness to steroids. 40 In another placebo-controlled trial of 283 young children with wheezing, prednisolone did not significantly decrease the overall time to discharge; however, it reduced by half the length of stay in children infected with picornavirus and by fourfold that of children with enterovirus, suggesting that response may be organism-dependant. 41 Clearly, oral corticosteroids may not 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9 be as effective in patients with viral infections as in those without, perhaps due to neutrophilic airway inflammation, a condition associated with poor response to corticosteroids. Moreover, response may be organism-specific, a hypothesis that requires careful documentation of aetiology.
Exposure to tobacco smoke
In addition to the aforementioned trial demonstrating no response to oral corticosteroids in asthmatic adult smokers, 22 a blunted response to inhaled corticosteroids was also documented in adult smokers in two randomized controlled trials. 42;43 While the mechanism behind the lack of response is not known, one can certainly point to smoking's direct toxicity, pro-inflammatory action, or interference with the transcription of genes associated with corticosteroid response. 22 Indeed, smoking has frequently been associated with airway neutrophilia. 44 In paediatrics, exposure to tobacco smoke has been associated with a higher incidence of URTIs and prevalence of asthma, and a greater severity of exacerbations. 45 However, the impact on the therapeutic response has not been documented in children, as asthma trials have not examined or failed to report subgroup analyses on ETS exposure or active smoking. Heavier ETS exposure in preschoolers who spend more time at home than school-aged children 46 ,47 may explain a poorer response in young children. Objective documentation of smoking would also be important if possible, even before high school where many already smoke. 48 Of particular concern is whether a blunted response to oral corticosteroids would be found in children exposed to tobacco smoke and adolescents with a short history of active smoking. With 25% of asthmatic children exposed to ETS and 25% of teenagers actively smoking, [49] [50] [51] such an assessment appears critical. 
Mechanistic pathways
Two promising mechanistic pathways may explain the variations in the magnitude of response observed in clinical effectiveness, namely (1) gene polymorphisms that may reveal potential geneenvironment interactions, and (2) the type of airway inflammation.
Gene polymorphisms
There is increasing evidence that inherited genes are not a deterministic genotype, but rather a genotype that encodes a potential range of phenotypes that will develop in response to a variety of environments. 64 Consequently, minor polymorphism between individuals in genes that modulate with an increased risk of asthma 75 and rapid decline of lung function among smokers. 76 The ADRB2 receptor gene was found to contribute to the occurrence of wheeze among children who were exposed to tobacco smoke in utero and early childhood 77 and related to β 2 -agonist response. 68;78 Among genes affecting the corticosteroid and inflammatory pathways, we selected genes (CHRH1, TBX21 FCER2, GLCC1, STIP1 and SERPINE1) that were shown to correlate with response to corticosteroids in patients with asthma; the finding for some of them was replicated in several cohorts. 79-82;82-84 All selected polymorphisms with the gene name, position and corresponding reference are summarized in Table. Genotyping is essential to link the observed corticosteroid response to genotype and to evaluate potential host-environment interaction. and combined eosinophilic/neutrophilic (≥2.5% eosinophils and >54% neutrophils) in 35%, with paucigranular inflammation not described in acute paediatric athma.
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Combined eosinophilic/neutrophilic exacerbations show more mast cells and higher sputum ECP levels than eosinophilic exacerbations. There is increasing evidence that eosinophilic asthma is more responsive to corticosteroids than non-eosinophilic asthma; a promising mechanistic pathway to explore.
93;94
Expired nitric oxide (eNO) is increasingly recognized as a non-invasive marker of airway inflammation, particularly in atopic asthma, 95;96 and correlates strongly with the percentage of airway eosinophils (r=0.78) and ECP (r=0.53) in children with asthma. 97 Although the understanding about the link between NO and airway inflammation remains incomplete, airway epithelial cells activated by inflammatory cytokines produce increased amount of eNO due to the expression of inducible NO synthase (iNOS). 98 Expired NO is elevated in untreated asthma 99 and improves with asthma therapy. 100;101 Of interest, eNO correlates with other markers of eosinophilic inflammation, including sputum eosinophils. 102;103 Thus, eNO appears to reflect the magnitude of eosinophilic airway inflammatory and may serve as a promising biomarker of eosinophilic inflammation in children too young or unable to cooperate with induced sputum sampling. 104 As it can be measured in preschool-aged using offline technique 105;106 and in older children using commercially available instruments, 107;108 it could serve as biomarker of subsequent response to corticosteroids if indeed, the type of airway inflammation modulates response.
Selection of Outcomes

Health care service utilisation
The need for hospital admission is a powerful marker of therapy failure, likely to alter physicians' practice and influence decision makers as hospital costs alone account for 43% of total asthma costs. 109 Although subject to practice variation, physician's decision to admit is usually based on an unsatisfactory response to bronchodilators and systemic corticosteroids in the ED, indicating severe asthma or poor response to corticosteroids. 22 Admission may be affected by other reasons, such as parental anxiety, distance, or fatigue, and of course, availability of ED and hospital beds. 50 Adding a cutoff length of ED stay, above which a patient is considered admitted, limits the impact of external factors (bed availabilities) which may vary widely within and between institutions. Moreover, incorporating return visits resulting in admission provides an additional measure of failure of ED treatment by adding a measure of the decision appropriateness. Time to meeting severity criteria for discharge (PRAM<4) and length of active treatment are two additional measures of interest, less influenced by factors other than severity. Clinical scores appear to be a reasonable alternative to lung function testing as they can be used in children of all ages. Although many clinical scores have been designed, only two have been validated for use in both preschool and school-aged children. 112;117 The PRAM is the only score developed and validated against a concurrent measure of lung function in children aged 3 to 6 years, 117 and subsequently validated in children aged 1 to 17 years. 23 It is a discriminative and responsive tool, with a change in scores ≥3 indicating clinical importance. 23;117 The inter-rater reliability is consistently above 70%. 23 The 12-point PRAM, rating five weighted items (oxygen saturation, suprasternal retractions, scalene muscle contraction, air entry, and wheezing) has been used in landmark clinical trials. 21 It can be used to assess severity at baseline (mild: PRAM 0 to 3; moderate: PRAM 4 to 7; severe: PRAM 8 to 12), improvement with treatment depicted as the area under the curve, need for admission (PRAM≥5, 8 hours after the oral corticosteroids) and time until ready for discharge (delay until PRAM<4). 
Indicators of airway dysfunction
Indicators of recovery following discharge
Among children discharged home, the time to complete recovery will vary widely between individuals.
Although symptom scores are frequently used in clinical trials, only four have been specifically developed for use in children. 69, 70, 71 The Asthma flare-up diary for young children © (formerly the Pediatric Asthma Diary) is the only one validated to detect day-to-day change in the functional status of preschool-aged children following an acute care visit; 118 it is highly sensitive to detect group differences in intensity and duration of symptoms in randomized controlled trials; however its performance in school-aged children has not been explored. 119 Another diary has been validated for detecting change in school-aged children but not in the context of acutely ill children. 120 Use of ß 2 -agonists is an additional marker for the duration and intensity of symptoms, as greater use of rescue relievers is expected to occur in children with more symptoms. 119 Finally, the impact of the disease on the quality of life of the patient or the caregivers is a recognized sensitive and unique marker of the burden of disease on the patient or family. 121 Several well-validated asthma-specific quality of life instruments are available for adults, 122 and school-aged children with stable asthma. 123 To our knowledge, only one instrument, entitled "Effects of a child's asthma flare-up on parents" is available for measuring the burden of disease on parents of preschool-aged children following an asthma exacerbation; we have developed the instrument using the Kirshner and Guaytt's approach for developing health instruments, 124 validated it in a randomized controlled trial, 119 and received two copyrights (French version:#1019528 English version:
#1019529. (Manuscript in preparation).
Hypothesis
In children presenting with moderate or severe asthma to the ED: 2. Specific genetic polymorphisms alone or in association with environmental factors are associated with higher risk of admission.
3. An eosinophilic pattern of airway inflammation (i.e.. percentage of eosinophils on induced sputum and/or baseline eNO) is associated with greater clinical improvement as measured by the PRAM area under the curve over 4 hours (nested cohort).
OBJECTIVES
The main objective is to identify and quantify clinically available factors (e.g., age, specific viral trigger, ETS) associated with hospital admission and other markers of clinical response to oral corticosteroids in preschool and school-aged children presenting to the ED with moderate or severe asthma.
Secondary objectives
1. Examine the association between specific genetic polymorphisms (including potential hostenvironment interactions) and markers of response 2. Determine whether the type of airway inflammation (i.e., eosinophilic and eNO) is associated with the magnitude of response to corticosteroids and which host or episode characteristics are associated specific type of inflammation
METHODS
Design
The study design is a multicentre prospective cohort study with a standard intervention involving 1008 children aged 1 to 17 years old presenting with acute asthma to one of the five participating Canadian paediatric emergency departments. The study includes a nested cohort study of children presenting at Patients will be excluded if they present: (1) with another chronic respiratory condition (such as bronchopulmonary dysplasia or cystic fibrosis); (2) with a reasonable suspicion of bronchiolitis or foreign body aspiration; (3) a prior history of hypersensitivity to salbutamol, ipratropium bromide or oral prednisolone; (4) a relative or absolute contraindication to receiving oral corticosteroids such as recent exposure to varicella or live vaccine in a susceptible child, or (5) with confirmed or suspected pregnancy status As some inclusion and exclusion criteria may become evident during or after the ED stay(i.e., pneumonia), a central adjudicating committee comprised of a paediatrician/ED physician and respirologist/radiologist will review the eligibility criteria of children, who after enrolment, appear to be 18 ineligible due to failure to meet one or more inclusion or exclusion criteria and who did not receive or tolerate oral corticosteroids as recommended in the protocol. The main trigger for identifying these children will be the ED physician low degree of confidence that this child had asthma and that he/she did not have bronchiolitis and the suspicion that he/she retain the corticosteroids. In this case, the relevant CRFs, relevant anonymized laboratory testing (i.e. imaging, microbiology, virology, haematology), and relevant anonymized medical chart sections will be reviewed by the adjudicating committee. The adjudicating committee will be central, although we are not ruling out the possibility of creating local committees at each site, depending on the volume of cases to review. In such a case, the site would be added as covariate in the analysis. Disagreement will be resolved by consensus or the assistance of a third observer. The proportion of excluded children, assumed to be around 10%, will be monitored and reported.
Standardized acute treatment protocol
As per the evidence-based paediatric national 127 and international guidelines, 9 children will be treated according to a standardized severity-specific protocol (Table) . All children will receive 2 mg/kg (max.
50 mg) of oral prednisolone (or prednisone) within 60 minutes of triage, along with inhaled salbutamol with or without inhaled ipratropium bromide as per severity strata. Discharge medications will include a 5-day course of oral prednisolone at a dose of 1 mg/kg/day and inhaled β 2 -agonists as needed. Cointerventions, such as add-on therapy with magnesium sulphate in the ED or inhaled corticosteroids at discharge will be permitted and recorded. Comorbidities (e.g., pneumonia, sinusitis, allergic rhinitis, etc.) and adverse health events will be documented. The primary outcome, serving as proxy for suboptimal response, is the hospital admission defined as a hospital admission for asthma (as primary or secondary diagnosis if the primary is a complication or comorbidity of asthma) or ED stay for asthma (with active treatment) of ≥8 hours after intake of oral corticosteroids. The 8-hour time constraint was included to account for extraneous factors affecting admissions, such as variation in bed availabilities while the child remains under treatment on site.
Measurements of effectiveness
Secondary measures of effectiveness in the ED include: (i) meeting the severity criteria for admission, that is, a PRAM score ≥4 within 4 hours of corticosteroids administration (to account for other reasons for hospital admission); (ii) the PRAM profile in the ED, measured hourly from baseline and every hour until disposition (or until 4 hrs. after intake of oral corticosteroids, whichever occurs first) and reported as the area under the curve; (iii) time to PRAM ≤ 3, that is, meeting the criteria for discharge;
(iv) length of active treatment defined as duration between the first and last salbutamol inhalation.
Finally, to allow more objective and precise quantification of response in a nested cohort (CHU SteJustine), (v) change in respiratory resistance between baseline and disposition will be documented on the MasterScreen Impulse Oscillometry (Cardinal Health Canada, Montreal, Canada) using previously described standardized techniques 110;114;126 in cooperative children aged ≥3 years, (vi) change in expired nitric oxide between baseline and disposition will be documented on an chemiluminescence nitric oxide analyser in cooperative children aged ≥4 years and (vii) failure of ED treatment defined a meeting the hospital admission criteria defines as the primary outcome or discharge with hospital admission for asthma (as primary or secondary diagnosis) within 72 hrs. or discharge with a return visit within 72 hrs. for asthma (as primary or secondary diagnosis) with an active ED stay of ≥8 hours.
Secondary measures of resolution of exacerbation measured after discharge will be documented over the next 10 days in all patients: (viii) unscheduled visits for asthma as reported by parents and confirmed by 
Potential determinants
Socio-demographic variables. Basic characteristics will be documented, including age, gender, neighbourhood financial income derived from 6-digit postal codes from both parents (if separated), medical insurance (private or public), and ethnicity as reported by the parents and classified as per the latest Canadian Census questionnaire.
Phenotype and morbidity.
Children's asthma phenotype will be documented as per the latest international recommendations (i.e., viral-induced, exercise-induced, allergen-induced, multipletrigger). 31 Prior morbidity (admissions, ED visits, rescue oral corticosteroids), asthma control using the Asthma Quiz for Kidz, 128 reported use of daily controller medications, environmental factors (e.g. dust, animals, pollen), and perceived trigger of the exacerbation will be documented. Prior allergy test results, serum IgE (specific) will be obtained (with permission) as well as pollen counts in the area.
Viral trigger. Acknowledging viruses as the major trigger
, all children will be tested for respiratory viruses. All children will have a nasopharyngeal aspirate (NPA) or nasopharyngeal swab (Flocked swab, Copan Diagnostics, CA) performed. The aspirate or swab will be put in 3 mL of viral transport media (UTM, Copan Diagnostics, CA) and split in half on site.
The first half will be tested using routine methods in each site if clinically required and the other half will be frozen at -80°C for molecular Passive exposure to tobacco smoke will be quantified by questionnaire specifically enquiring about current and amount of smoking by household members, cumulative smoke exposure in pack-years since birth, and in utero exposure, using validated questions. 51;130 Active smoking will be assessed by asking school-aged children aged 10 years and older, while alone, if they smoked in the past 7 days, using standardized questions used by the Quebec Institute of Statistics. 131 A quantitative cotinine by quantitative enzyme immunoassay kit (Salimetrics, PA, USA) will be performed on saliva sampled using three Sorbettes (a wand with a small sponge) according to a previously described protocol.
56,57
Several other factors will be considered, including assumed trigger. In absence of valid biomarkers of causal relationship to the exacerbation, the alleged trigger (allergic or other) based on parental report, physician perception, prior documented sensitization (skin tests or specific IgE), pollen, particles, ozone (and other) levels in the child's living area will serve to infer trigger.
Mechanistic pathway
Genetic profile. Patients' DNA will be extracted from saliva expectoration or collected on Sorbettes designed for young children, with only a small amount (1-2 mL) needed for DNA analysis. After amplification by PCR, key polymorphisms 132;133 will be determined by high throughput genotyping technology (Sequenom platform) for custom SNP panels.
Expired nitric oxide (eNO) will be measured on a chemiluminescence analyser (the Niox Flex or the portable Niox Mino from Aerocrine, New Providence, NJ, USA or Sievers from GE Analytic Instrument, Boulder, CO, USA), using standardized techniques 98 in cooperative children aged ≥4 years; 22 the measurements will be taken before corticosteroids and at 4 hours or disposition, whichever occurs first. In children unable to cooperate with these techniques, the eNO will also be measured, using the single breath manoeuvre, in an inert balloon (offline technique) and then analysed on the chemiluminescence analyzer.
105;106
Induced sputum. After the initial salbutamol inhalation, children aged ≥7 years will be asked to expectorate spontaneously or, if unsuccessful, receive a nebulisation of 0.9% saline solution over 7 to 10 minutes at 5 L/min with oxygen 152 . With this technique, a 70% success rate was obtained among acutely ill school-aged asthmatic children. [134] [135] [136] Throughout the induction, lung function tests using respiratory resistance will be documented to ensure that the coughing effort do not induce bronchospasm. 134 Sputum will be processed according to standard techniques within 8 hours of. Briefly, sputum will be separated from saliva and dispersed using dithiothreitol. The dispersed suspension is then centrifuged and filtered; cytospin slides will be prepared on site by a trained medical technologist, and the supernatant frozen at -70°C for subsequent quantification of inflammatory mediators. Differential cell counts and inflammatory mediators will each be analysed by an independent laboratory, blinded to exposure and outcome.
Procedures
Within each institution, potentially eligible patients aged 1 to 17 years will be identified upon arrival in the ED. As per standard practice in each participating hospitals, all children will be triaged and scored on the PRAM at or shortly after triage. The first inhalation of salbutamol and, for severe exacerbations, ipratropium bromide, will be administered ( Figure) . Using a 2-step informed consent, parents will first
give their authorization for their child to receive standardized severity-specific treatment and, at the CHU Ste-Justine, lung function testing and induced sputum in cooperative children. Parents will then receive a detailed explanation of the study and be offered study participation. Participants will receive the treatment and measures detailed in Figure, with key measurements obtained prior to corticosteroids.
Statistical analyses
Standard summary statistics (N, mean, standard deviation, median, minimum and maximum for continuous variables; N and proportion for categorical variables) will be computed for all variables for the whole cohort and by institutions. Two-sided 95% confidence intervals will be presented as necessary.
For the primary endpoint, hospital admission, and other dichotomous outcomes, bivariate and multivariate logistic regression models will be used to examine the association with each potential determinant and to adjust for site, baseline severity, and other relevant covariates of interest. Odds ratios will be estimated and presented with two-sided 95% confidence intervals. Continuous outcomes such as the area under the curve for repeated PRAM measures, daily Asthma flare-up diary for young children© or intensity of both ß 2 -agonist use and symptom scores after discharge, will be analysed using linear regression models. Transformation of variables will be performed if necessary to account for nonnormality of the residuals.
With regards to pharmacogenomics, we will compare the frequency of SNPs between patients admitted vs. discharged using Fisher's exact tests and examine the strength of the association with admission with bivariate and multivariate logistic regression. Genotypes will be considered as variables with two (dominant or recessive models) or three (additive model) categories. The choice of the model is determined by the functionality of selected polymorphisms and previous reports. Bonferroni correction will be used to adjust for multiple testing (p=0.005, adjusted for 10 independent genes investigated).
Host-environment interaction will be examined by adding to the genotype model, other covariates of interest. For example, to investigate genetic heterogeneity according to early-life exposure to environmental tobacco smoke, we will introduce markers of tobacco smoke exposure status. With regards to examining eosinophilic inflammation as a marker of responsiveness, the area of the curve of serial PRAM measurements and time to PRAM<4, will serve as outcomes. Linear regression will be used to examine the bivariate and multivariate relationship between sputum eosinophils counts, patterns of inflammation (eosinophilic, non-eosinophilic and mixed), and baseline eNO with the PRAM profile (area under the curve); standard survival curve will explore the difference in time to meeting criteria for discharge, censored at 4 hours. 137 All models will be checked using appropriate regression diagnostics. Results will be reported as significant when p<0.05.
Sample size
Sample size was estimated in two steps using hospital admission as the dependant variable in a multivariate logistic regression model. Pilot data were extracted from two large recent chart audits 14;138 totalling 1628 children presenting with acute asthma to the ED (in which age, gender, baseline PRAM, timing of oral corticosteroids intake and admission were documented) and two recently completed trials 119;139 totalling 518 children, in whom tobacco exposure was also ascertained by questionnaire; we then focused only on children meeting our current eligibility criteria (age, baseline PRAM, corticosteroids within an hours of arrival). Based on the literature, we assumed the prevalence of viral pathogen varied between 60% and 80%. 140;141 The baseline risk of admission was 41%; after recruitment of the initial 320 patients, the observed overall risk of admission was substantially lower at 16%, which substantially reduced the effective sample size from 1200 to 800. First, using the Wald test (using prevalence of factor and risk of admission in unexposed), we calculated the sample size required to detect a risk difference (RD) of admission of 7.5%, taking each determinant in turn as the independent variable in a bivariate logistic regression; we used 95% confidence intervals for each estimate obtained from pilot data to examine the impact on power. 142 Then, using the method proposed by Hsieh et al. we calculated the inflation factor to adjust the total sample size, based on the observed correlation between key determinants (age, gender and tobacco exposure, and baseline severity). As the observed correlation between determinants and severity and any pair of determinants was negligible (Phi coefficients < 0.03), there was no need to inflate the sample size. At an alpha of 0.05, a sample of 800 children had 80% power to detect a risk difference of admission of ≥7.5% for all key determinants. We targeted the risk difference of 7.5%, because it was considered in a survey of researchers of the Pediatric Emergency Research in Canada (PERC) network as a clinically meaningful effect size that would support a practice change. After documenting a 1% lost after enrolment (from 10% originally estimated) and 20% missing key samples (viral or cotinine), our target recruitment sample is 1008 to obtain an effective sample of 800 children. Acknowledging that the majority of selected polymorphisms have a minor allele frequency of at least 30% and using an alpha of 0.005 (with Bonferroni correction for 14 polymorphisms), 1008 children will provide 80% power to detect an OR of 1.5 between each polymorphism and admission. Finally, of the expected 400 children recruited at the University Health
Centre Sainte-Justine, we estimated that 200 children would cooperate with eNO measurements and 60 with induced sputum.. These sample sizes should be adequate to detect a correlation coefficient as low as 0.2 to 0.35, respectively, with the area under the curve of the PRAM score during the ED with 80%
power and a two-sided 0.05 α.
ETHICS AND DISSEMINATION
This study poses little risk to participants, as all children will receive state-of-the-art asthma management with oral corticosteroids, an approach associated with minimal side effects. 19;144;145 Children will be assessed for potential contraindication to corticosteroids prior to enrolment. Using a 2-step informed consent, parents will first give their authorization for their child to receive the severity-specific asthma protocol and, at specific centres, lung function testing and induced sputum in cooperative children; then they will consent to the full study including sampling for cotinine, DNA, and viruses. All parents will sign an informed consent form authorizing the DNA analysis for the specified research purpose as well as future analyses (including biobanking of DNA in anonymized fashion), provided these are approved by the Institutional Ethics Boards. Assent will be obtained from children aged 7≥years. The collection of saliva by expectoration or sponge is painless, well tolerated by children. Nasopharyngeal aspiration or swab for viral diagnosis is a commonly used procedure in the ED setting; it is rapid and associated with little discomfort. The performance of respiratory resistance and eNO is non-invasive and devoid of serious side effects. Sputum induction with 0.9% saline and salbutamol pre-treatment is a safe procedure in the acute care setting. [134] [135] [136] Data safety is maximized through: restricted physical access to computers and electronically protected servers (firewall, restricted password-protected access, daily back-up, and storage in 2 different locations). Confidentiality is also part of standard operating procedures; a unique research code will be assigned to each patient. All research data and specimens will be kept in locked rooms with restricted access at each site, the coordination centre, and the site of analysis. The protocol, consent form and any amendments are subject to the Ethics Review Board approval of each institution.
Each investigator will adhere to the principles of the Declaration of Helsinki. All serious adverse effects will be promptly reported.
This study will provide needed answers as to whether oral corticosteroids are less effective for preventing hospital admission in subgroups of children, and if so, which clinically available characteristics could be used to identify patients at risk of poorer response. An impaired response to systemic steroids in certain subgroups resulting in a higher rate of hospital admission and/or impaired recovery, would challenge the current standard of practice and call for the immediate search for better approaches. Given the high prevalence of suspected factors (young age (60%), viral infection (60-80%), environmental tobacco smoke (20-30%)), the potential impact of poor response on the rate of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
